In vitro activities of antibiotic combinations against clincal isolates of Pseudomonas aeruginosa (Q44976445)

7 December 2017

In vitro activities of antibiotic combinations against clincal isolates of Pseudomonas aeruginosa (English)

1 reference

7 December 2017

Pseudomonas aeruginosa

1 reference

Yen-Hsu Chen

1

1 reference

7 December 2017

Chien-Fang Peng

2

1 reference

7 December 2017

Po-Liang Lu

3

1 reference

7 December 2017

Jih-Jin Tsai

4

1 reference

7 December 2017

Tyen-Po Chen

5

1 reference

7 December 2017

1 June 2004

1 reference

Kaohsiung Journal of Medical Sciences

7 December 2017

1 reference

7 December 2017

20

1 reference

7 December 2017

6

1 reference

7 December 2017

261-267

1 reference

National Nosocomial Infections Surveillance (NNIS) System Report, data summary from January 1992 through June 2003, issued August 2003.

7 December 2017

1 reference

https://api.crossref.org/works/10.1016%2FS1607-551X%2809%2970116-0

7 January 2021

Predominant pathogens found in the European Prevalence of Infection in Intensive Care Study

1 reference

https://api.crossref.org/works/10.1016%2FS1607-551X%2809%2970116-0

7 January 2021

Health and economic outcomes of antibiotic resistance in Pseudomonas aeruginosa

1 reference

https://api.crossref.org/works/10.1016%2FS1607-551X%2809%2970116-0

7 January 2021

Imipenem-resistant Pseudomonas aeruginosa: risk factors and antibiotic susceptibility patterns

1 reference

https://api.crossref.org/works/10.1016%2FS1607-551X%2809%2970116-0

7 January 2021

Antibiotic therapy for Pseudomonas aeruginosa bacteremia: outcome correlations in a prospective study of 200 patients

1 reference

https://api.crossref.org/works/10.1016%2FS1607-551X%2809%2970116-0

7 January 2021

In vitro activities of aztreonam, piperacillin, and ticarcillin combined with amikacin against amikacin-resistant Pseudomonas aeruginosa and P. cepacia isolates from children with cystic fibrosis

1 reference

https://api.crossref.org/works/10.1016%2FS1607-551X%2809%2970116-0

7 January 2021

Comparison of the antibacterial activities of the quinolones Bay 12-8039, gatifloxacin (AM 1155), trovafloxacin, clinafloxacin, levofloxacin and ciprofloxacin

1 reference

https://api.crossref.org/works/10.1016%2FS1607-551X%2809%2970116-0

7 January 2021

Synergy, antagonism, and what the chequerboard puts between them

1 reference

https://api.crossref.org/works/10.1016%2FS1607-551X%2809%2970116-0

7 January 2021

Current status of antimicrobial resistance in Taiwan

1 reference

https://api.crossref.org/works/10.1016%2FS1607-551X%2809%2970116-0

7 January 2021

Characterization of Pseudomonas aeruginosa isolates: occurrence rates, antimicrobial susceptibility patterns, and molecular typing in the global SENTRY Antimicrobial Surveillance Program, 1997-1999.

1 reference

https://api.crossref.org/works/10.1016%2FS1607-551X%2809%2970116-0

7 January 2021

Antibiotic susceptibility among aerobic gram-negative bacilli in intensive care units in 5 European countries. French and Portuguese ICU Study Groups

1 reference

https://api.crossref.org/works/10.1016%2FS1607-551X%2809%2970116-0

7 January 2021

Geographic variations in activity of broad-spectrum beta-lactams against Pseudomonas aeruginosa: summary of the worldwide SENTRY Antimicrobial Surveillance Program (1997-2000).

1 reference

https://api.crossref.org/works/10.1016%2FS1607-551X%2809%2970116-0

7 January 2021

In vitro activities of combinations of aztreonam, ciprofloxacin, and ceftazidime against clinical isolates of Pseudomonas aeruginosa and Pseudomonas cepacia from patients with cystic fibrosis

1 reference

https://api.crossref.org/works/10.1016%2FS1607-551X%2809%2970116-0

7 January 2021

In vitro synergy studies with ciprofloxacin and selected beta-lactam agents and aminoglycosides against multidrug-resistant Pseudomonas aeruginosa

1 reference

https://api.crossref.org/works/10.1016%2FS1607-551X%2809%2970116-0

7 January 2021

In vitro and in vivo antibacterial effects of combinations of beta-lactam antibiotics

1 reference

https://api.crossref.org/works/10.1016%2FS1607-551X%2809%2970116-0

7 January 2021

Cefepime-aztreonam: a unique double beta-lactam combination for Pseudomonas aeruginosa

1 reference

https://api.crossref.org/works/10.1016%2FS1607-551X%2809%2970116-0

7 January 2021

Contemporary in vitro synergy rates for aztreonam combined with newer fluoroquinolones and β-lactams tested against gram-negative bacilli

1 reference

https://api.crossref.org/works/10.1016%2FS1607-551X%2809%2970116-0

7 January 2021

Comparative activity of cefepime, alone and in combination, against clinical isolates of Pseudomonas aeruginosa and Pseudomonas cepacia from cystic fibrosis patients

1 reference

https://api.crossref.org/works/10.1016%2FS1607-551X%2809%2970116-0

7 January 2021

Pharmacodynamics of once-daily amikacin in various combinations with cefepime, aztreonam, and ceftazidime against Pseudomonas aeruginosa in an in vitro infection model

1 reference

https://api.crossref.org/works/10.1016%2FS1607-551X%2809%2970116-0

7 January 2021

Synergic activity of cephalosporins plus fluoroquinolones against Pseudomonas aeruginosa with resistance to one or both drugs

1 reference

https://api.crossref.org/works/10.1016%2FS1607-551X%2809%2970116-0

7 January 2021

Timed killing kinetic studies of the interaction between ciprofloxacin and beta-lactams against gram-negative bacilli

1 reference

https://api.crossref.org/works/10.1016%2FS1607-551X%2809%2970116-0

7 January 2021

Synergistic activities of gatifloxacin in combination with other antimicrobial agents against Pseudomonas aeruginosa and related species

1 reference

https://api.crossref.org/works/10.1016%2FS1607-551X%2809%2970116-0

7 January 2021

In vitro activity of ciprofloxacin, levofloxacin, and trovafloxacin, alone and in combination with beta-lactams, against clinical isolates of Pseudomonas aeruginosa, Stenotrophomonas maltophilia, and Burkholderia cepacia

1 reference

https://api.crossref.org/works/10.1016%2FS1607-551X%2809%2970116-0

7 January 2021

In vitro activity of beta-lactams in combination with other antimicrobial agents against resistant strains of Pseudomonas aeruginosa

1 reference

https://api.crossref.org/works/10.1016%2FS1607-551X%2809%2970116-0

7 January 2021

Comparison of methodologies for synergism testing of drug combinations against resistant strains of Pseudomonas aeruginosa

1 reference

https://api.crossref.org/works/10.1016%2FS1607-551X%2809%2970116-0

7 January 2021

Determination of activities of levofloxacin, alone and combined with gentamicin, ceftazidime, cefpirome, and meropenem, against 124 strains of Pseudomonas aeruginosa by checkerboard and time-kill methodology

1 reference

https://api.crossref.org/works/10.1016%2FS1607-551X%2809%2970116-0

7 January 2021

Activity of piperacillin/tazobactam in combination with amikacin, ciprofloxacin, and trovafloxacin against Pseudomonas aeruginosa by time-kill.

1 reference

https://api.crossref.org/works/10.1016%2FS1607-551X%2809%2970116-0

7 January 2021

10.1016/S1607-551X(09)70116-0

Identifiers

DOI

1 reference

7 December 2017

1 reference